Recently, elevated ERK1/2 phosphorylation was associated with shorter survival in patients with HNSCC.44–46 These studies provide evidence for a potential role of activated ERK1/2 as a predictive biomarker of clinical outcomes for HNSCC patients treated with RT, CT and/or cetuximab. This evidence concerns the gene MAPK3 and head and neck squamous cell carcinoma.